Estrogen carcinogenesis in breast cancer

New England Journal of Medicine

Volumn 354, Issue 3, 2006, Pages

  Yager, James D ^a,c   Davidson, Nancy E ^b  

^a The Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; FULVESTRANT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; TAMOXIFEN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DNA DAMAGE; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOTOXICITY; HORMONAL CARCINOGENESIS; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; CARCINOGENS; DNA DAMAGE; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 30944469849     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra050776     Document Type: Review

References (114)

1. Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86.
2. Santen R. Endocrine-responsive cancer. In: Larson PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia: W.B. Saunders, 2003:1797-833.
3. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85. [Erratum, N Engl J Med 2001;344:1804.]
4. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
5. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
6. Onland-Moret NC, Kaaks R, Van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003;88:1394-9.
7. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast-cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
8. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
9. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.
10. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer: Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59. [Erratum, Lancet 1997;350:1484.]
11. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast-cancer risk. JAMA 2000;283:485-91. [Erratum, JAMA 2000;284:2597.]
12. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-54.
13. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
15. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
16. Post-menopausal oestrogen therapy. Lyon, France: International Agency for Research on Cancer, 1999. (IARC scientific publications no. 72.)
17. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. [Erratum, Lancet 2003;362:1160.]
18. Speroff L. The Million Women Study and breast cancer. Maturitas 2003;46:1-6.
19. Gambacciani M, Genazzani AR. The study with a million women (and hopefully fewer mistakes). Gynecol Endocrinol 2003;17:359-62.
20. Olsson H. What can we learn from the Million Women Study. Maturitas 2003;46:87-9.
21. Hulley SB, Grady D. The WHI estrogenalone trial - do things look any better? JAMA 2004;291:1769-71.
22. Breast cancer and hormonal contraceptives: further results. Contraception 1996;54:Suppl 3:1S-106S.
23. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
24. Druckmann R. Progestins and their effects on the breast. Maturitas 2003;46:Suppl1:S59-S69.
25. Yang X, Edgerton SM, Kosanke SD, et al. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 2003;63:2425-33.
26. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 1995;92:3650-7.
27. Harvell DM, Strecker TE, Tochacek M, et al. Rat strain-specific actions of 17betaestradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci U S A 2000;97:2779-84.
28. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL. Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997;18:1595-601.
29. Turan VK, Sanchez RI, Li JJ, et al. The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 2004;183:91-9.
30. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
31. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. In: Estrogens as endogenous carcinogens in the breast and prostate. Journal of the National Cancer Institute monograph. No. 27. Bethesda, Md.: National Cancer Institute, July 2000:67-73.
32. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. In: Estrogens as endogenous carcinogens in the breast and prostate. Journal of the National Cancer Institute monograph. No. 27. Bethesda, Md.: National Cancer Institute, July 2000:75-93.
33. Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. In: Estrogens as endogenous carcinogens in the breast and prostate. Journal of the National Cancer Institute monograph. No. 27. Bethesda, Md.: National Cancer Institute, July 2000:95-112.
34. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000;21:40-54.
35. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81.
36. Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 2000;60:4667-77.
37. Devanesan P, Todorovic R, Zhao J, Gross ML, Rogan EG, Cavalieri EL. Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogen-initiated cancer. Carcinogenesis 2001;22:489-97.
38. Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG. Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 2001;14:1041-50.
39. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces errorprone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
40. Lavigne JA, Goodman JE, Fonong T, et al. The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradioltreated MCF-7 cells. Cancer Res 2001;61:7488-94.
41. Nutter LM, Ngo EO, Abul-Hajj YJ. Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. J Biol Chem 1991;266:16380-6.
42. Nutter LM, Wu YY, Ngo EO, Sierra EE, Gutierrez PL, Abul-Hajj YJ. An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem Res Toxicol 1994;7:23-8.
43. Nutter LM, Zhou B, Sierra EE, et al. Cellular biochemical determinants modulating the metabolism of estrone 3,4-quinone. Chem Res Toxicol 1994;7:609-13.
44. Seacat AM, Kuppusamy P, Zweier JL, Yager JD. ESR identification of free radicals formed from the oxidation of catechol estrogens by Cu2+. Arch Biochem Biophys 1997;347:45-52.
45. Mobley JA, Bhat AS, Brueggemeier RW. Measurement of oxidative DNA damage by catechol estrogens and analogues in vitro. Chem Res Toxicol 1999;12:270-7.
46. Li Y, Trush MA, Yager JD. DNA damage caused by reactive oxygen species originating from a copper-dependent oxidation of the 2-hydroxy catechol of estradiol. Carcinogenesis 1994;15:1421-7.
47. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997;51:951-62.
48. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001;127:405-10.
49. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999;5:493-9.
50. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-77.
51. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
52. Dawling S, Roodi N, Parl FF. Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res 2003;63:3127-32.
53. Yao J, Li Y, Chang M, et al. Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase. Chem Res Toxicol 2003;16:668-75.
54. Yao J, Chang M, Li Y, et al. Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: specificity for glutathione S-transferase P1-1. Chem Res Toxicol 2002;15:935-42.
55. Li Y, Yao J, Chang M, et al. Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase. Chem Res Toxicol 2004;17:512-20.
56. Li KM, Todorovic R, Devanesan P, et al. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 2004;25:289-97.
57. Kong LY, Szaniszlo P, Albrecht T, Liehr JG. Frequency and molecular analysis of hprt mutations induced by estradiol in Chinese hamster V79 cells. Int J Oncol 2000;17:1141-9.
58. Samuni AM, Chuang EY, Krishna MC, et al. Semiquinone radical intermediate in catecholic estrogen-mediated cytotoxicity and mutagenesis: chemoprevention strategies with antioxidants. Proc Natl Acad Sci U S A 2003;100:5390-5.
59. Tsutsui T, Suzuki N, Fukuda S, et al. 17beta-Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. Carcinogenesis 1987;8:1715-9.
60. Tsutsui T, Tamura Y, Hagiwara M, et al. Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogenesis 2000;21:735-40.
61. Tsutsui T, Tamura Y, Yagi E, Barrett JC. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer 2000;86:8-14.
62. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;87:1-25.
63. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7.
64. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6.
65. Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
66. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer: the role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
67. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-47.
68. Miyoshi Y, Noguchi S. Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed Pharmacother 2003;57:471-81.
69. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997;57:5493-7.
70. Park SK, Yim DS, Yoon KS, et al. Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res Treat 2004;88:55-62.
71. Webb P, Nguyen P, Valentine C, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672-85.
72. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP responselike element. Proc Natl Acad Sci U S A 1999;96:11217-22.
73. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003;17:309-17.
74. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptoralpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:7998-8011.
75. Chen JQ, Delannoy M, Cooke C, Yager JD. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 2004;286:E1011-E1022.
76. Demonacos CV, Karayanni N, Hatzoglou E, Tsiriyiotis C, Spandidos DA, Sekeris CE. Mitochondrial genes as sites of primary action of steroid hormones. Steroids 1996;61:226-32.
77. Sekeris CE. The mitochondrial genome: a possible primary site of action of steroid hormones. In Vivo 1990;4:317-20.
78. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002;67:471-5.
79. Liao JK. Cross-coupling between the oestrogen receptor and phosphoinositide 3-kinase. Biochem Soc Trans 2003;31:66-70.
80. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994;91:8517-21.
81. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300.
82. Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116-27.
83. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002;80:239-56.
84. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 1999;13:307-19.
85. Razandi M, Pedram A, Levin ER. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 2000;14:1434-47.
86. Govind AP, Thampan RV. Membrane associated estrogen receptors and related proteins: localization at the plasma membrane and the endoplasmic reticulum. Mol Cell Biochem 2003;253:233-40.
87. Levin ER. Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001;91:1860-7.
88. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004;50:3-22.
89. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA. Update on estrogen signaling. FEBS Lett 2003;546:17-24.
90. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001;63:165-92.
91. Noteboom WD, Gorski J. Stereospecific binding of estrogens in the rat uterus. Arch Biochem Biophys 1965;111:559-68.
92. Monje P, Boland R. Subcellular distribution of native estrogen receptor alpha and beta isoforms in rabbit uterus and ovary. J Cell Biochem 2001;82:467-79.
93. Yang SH, Liu R, Perez EJ, et al. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A 2004;101:4130-5.
94. Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res 2004;78:861-71.
95. Chen JQ, Yager JD. Estrogen's effects on mitochondrial gene expression: mechanisms and potential contributions to estrogen carcinogenesis. Ann N Y Acad Sci 2004;1028:258-72.
96. Chen JQ, Eshete M, Alworth WL, Yager JD. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J Cell Biochem 2004;93:358-73.
97. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
98. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001;12:152-6.
99. Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997;62:268-303.
100. Schutze N, Vollmer G, Tiemann I, Geiger M, Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem Mol Biol 1993;46:781-9.
101. Schutze N, Vollmer G, Knuppen R. Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J Steroid Biochem Mol Biol 1994;48:453-61.
102. Hoogenboom LAP, de Haan L, Hooijerink D, Bor G, Murk AJ, Brouwer A. Estrogenic activity of estradiol and its metabolites in the ER-CALUX assay with human T47D breast cells. APMIS 2001;109:101-7.
103. Philips BJ, Ansell PJ, Newton LG, et al. Estrogen receptor-independent catechol estrogen binding activity: protein binding studies in wild-type, estrogen receptor-alpha KO, and aromatase KO mice tissues. Biochemistry 2004;43:6698-708.
104. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment. Lancet 1896;2:104-7.
105. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94:131-41.
106. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
107. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.
108. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breastcancer prevention trials. Lancet 2003;361:296-300.
109. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
110. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. [Erratum, N Engl J Med 2004;351:2461.]
111. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
112. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-870s.
113. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
114. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64:1522-33.